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Abstract
Introduction: Genetic predisposition to multiple sclerosis (MS) in Sardinia (Italy) has been associated with five DRB1*-DQB1*
haplotypes of the human leukocyte antigen (HLA). Given the complexity of these associations, an in-depth re-analysis was
performed with the specific aims of confirming the haplotype associations; establishing the independence of the associated
haplotypes; and assessing patients’ genotypic risk of developing MS.
Methods and Results: A transmission disequilibrium test (TDT) of the DRB1*-DQB1* haplotypes in 943 trio families,
confirmed a higher than expected transmission rate (over-transmission) of the *13:03-*03:01 (OR=2.9, P=7.6610
23),
*04:05-*03:01 (OR=2.4, P=4.4610
26) and *03:01-*02:01 (OR=2.1, P=1.0610
215) haplotype. In contrast, the *16:01-*05:02
(OR=0.5, P=5.4610
211) and the *15:02-*06:01 (OR=0.3, P=1.5610
23) haplotypes exhibited a lower than expected
transmission rate (under-transmission). The independence of the transmission of each positively and negatively associated
haplotype was confirmed relative to all positively associated haplotypes, and to the negatively associated *16:01-*05:02
haplotype. In patients, carriage of two predisposing haplotypes, or of protective haplotypes, respectively increased or
decreased the patient’s risk of developing MS. The risk of MS followed a multiplicative model of genotypes, which was, in
order of decreasing ORs: *04:05-*0301/*03:01-*02:01 (OR=4.5); *03:01-*02:01/*03:01-*02:01 (OR=4.1); and the *16:01-
*05:02/*16:01-*0502 (OR=0.2) genotypes. Analysis of DRB1 and DQB1 protein chain residues showed that the Val/Gly
residue at position 86 of the DRB1 chain was the only difference between the protective *16:01- *15:02 alleles and the
predisposing *15:01 one. Similarly, the Ala/Val residue at position 38 of the DQB1 chain differentiated the positively
associated *06:02 allele and the negatively associated *05:02, *06:01 alleles.
Conclusions: These findings show that the association of specific, independent DRB1*-DQB1* haplotypes confers
susceptibility or resistance to MS in the MS-prone Sardinian population. The data also supports a functional role for specific
residues of the DRB1 and DQB1 proteins in predisposing patients to MS.
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Introduction
The pathogenesis of multiple sclerosis (MS), the most common
disabling disease in young adulthood, is believed to be driven by
an inflammatory and degenerative process [1]. Many studies have
demonstrated that genetic factors play a role in MS predisposition
[2–4]. Susceptibility to the disease is conferred by a rather large
number of small genetic variants, as recently identified by a
genome wide association study [4], with the main genetic
determinant located at the human leukocyte antigen (HLA) class
II DRB1 and DQB1 loci. Indeed, since the 1972, MS has
consistently been associated with the Major Histocompatibility
(MHC) region [5]. Successive studies progressively refined the
association to the DR2 allele [6] and to specific molecular variants
[7], notably the HLA-DRB1*15 (*DRB1-15:01-DQA1*01:02-
DQB1*06:02) haplotype, which represents the main disease risk
factor in populations of North European origin [4]. However,
several different allelic associations are present in South European
populations [8–10] and in Israel [11], and other secondary DRB1*
allelic associations have been found in North European popula-
tions [4]. Together, these findings question the idea that only
products of molecular variants contained in the *15:01-
DQB1*06:02 haplotype are functionally responsible for the
autoimmune response to encephalitogenic peptides [12], which
causes MS. Moreover, in MS populations of North European
ancestry, several studies have determined the presence of alleles
conferring resistance and influencing predisposition to the disease
[13–16]. For instance, the effect of the *15:01 allele, which
maximally increases the MS risk in white populations of Northern-
European descent [4], is either cancelled by the co-presence of the
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33972*14 allele, or is reinforced by the co-presence of the *08 allele [14–
16]. The high degree of non-random association (linkage dis-
equilibrium, LD) across the MHC region represents an important
limit to understanding HLA-disease associations, which may
prevent the discrimination of whether an identified variant is the
causal gene, or it simply reflects LD. Suggestions that MS risk is
influenced by variations both at the DRB1 and the DQB1 region
also come from some studies in North European MS patient
cohorts [17,18]. In an attempt to gain insight on the role of HLA
class II molecules in inflammatory and demyelinating human
diseases such as MS, humanized animal models using transgenic
mice have been used. These models are able to express human
HLA-DR or –DQ genes, in absence of endogenous mouse class II
genes [12,19]. The role of both DRB1* and DQB1* molecules in
susceptibility and resistance to experimental autoimmune enceph-
alomyelitis (EAE) has recently been demonstrated in a HLA
double transgenic mouse, thus reinforcing the idea that a
synergism between DRB1* and DQB1* genes may contribute to
MS predisposition [20].
Sardinia is a major Italian island with a high incidence of MS
[21,22], distinguished by a unique, highly homogeneous genetic
make-up, resulting from fixation of alleles and haplotypes that are
elsewhere rare or absent [23]. For instance, the *03:01-*02:01
haplotype is extremely frequent, while the *15:01-*06:02 haplo-
type is only rarely observed in this population [23]. Such genetic
differentiation is extremely helpful in defining which HLA alleles
and motifs are shared between patients from distantly related
populations. A significant positive association with MS and five
HLA haplotypes, including the *13:03-*03:01, *04:05-*03:01,
*03:01-*02:01, *04:05-*03:02 and *15:01-*06:01 has been report-
ed in the Sardinian population, with different ranges of risk carried
by patients/individuals with each associated haplotype [24]. The
independence of associated haplotypes was not assessed in the
previously mentioned study and, despite the plethora of predis-
posing HLA molecules, significantly negatively associated haplo-
types did not emerge, when displacement effects driven by the
positively associated haplotypes were taken into account [24].
Thus, our aim in the present study is to re-analyse the MS risk
conferred by HLA class II variants and specifically determined by
both DRB1* and DQB1* alleles (DRB1*- DQB1* haplotype) in a
more consistent sample of Sardinian MS families. Our intent is to
confirm the haplotype associations, establish the independence of
the associated haplotypes and assess the risk due to the genotype of
Sardinian patients.
Results
Analysis of associated HLA-DRB1-DQB1 haplotypes
We first re-analysed the association of DRB1*-DQB1* haplo-
types in Sardinian MS patients. For this purpose, transmission
disequilibrium test (TDT) analysis was performed in a sample of
943 trio families. Only haplotypes represented in at least 1% of the
sample were considered. After correction for the 21 considered
haplotypes, three of them were found to be significantly over-
transmitted: *13:03-*03:01 (OR=2.9, 95% CI 1.6–5.4,
P=7.6610
23); *04:05- *03:01 (OR=2.4, 95% CI 1.7–3.4,
P=4.4610
26); and *03:01- *02:01 (OR=2.1, 95% CI 1.7–2.4,
P=1.0610
25). Also the *15:01- *06:02 haplotype appeared at first
to be over-transmitted (OR=1.9, 95% CI 1.1–3.3,P=1.4610
22),
but statistical correction greatly reduced the significance
(P=3.0610
21). Finally, two haplotypes resulted as under-
transmitted: *16:01-* 05:02 (OR=0.5, 95% CI 0.4–
0.6,P=5.4610
211) and *15:02- *06:01 (OR=0.3, 95% CI 0.1–
0.5, P=1.5610
23).
Transmission of the HLA-DRB1*-DQB1* haplotypes to unaf-
fected offspring was also examined in 362 healthy siblings
belonging to the 943 families (only one sibling per family was
considered in the analysis). Data are reported in Table 1.
As expected, there was no significant difference between trans-
mitted and un- transmitted haplotypes in healthy siblings (data not
shown)
Independence of the effect and mode of inheritance of
positively associated haplotypes
To avoid confounding results due to over-transmission, the
transmission of each positively associated DRB1*-DQB1* haplo-
type was assessed by analysing the segregation from parents who
carried only one associated haplotype, and removing all parents
who carried other associated haplotypes. Despite a small statistical
significance after correction, the *15:01-*06:02 haplotype was
considered ‘‘positively associated’’, partly because it is widely
regarded as a/the major genetic determinant in MS risk. The
analysis determined the risk to offspring that was conferred
by having one copy of each specifically associated haplotype,
independently from the other associated haplotypes (effect inde-
pendence); versus two copies of ‘‘neutral’’ haplotypes (dominant
effect); and the risk conferred by two copies versus one copy
(additive effect).
*13:03-*03:01. The independent effect of *13:03-*03:01 was
assessed by examining segregation of the haplotype in various
mating types from the genotype of both parents. Due to the
relative rarity of this haplotype, there were only 16 families
available for the analysis. Possible mating combinations are
*13:03-*03:01/*X by *X/*X, *13:03-*03:01/*X by *13:03-
*03:01/*X and *13:03-*03:01/*13:03-*03:01 by *13:03-*03:01/
*X (*X denotes haplotypes other than *13:03-*03:01, *04:05-
*03:01, *03:01-*02:01 and *15:01-*06:02). Only the haplotype
*13:03-*03:01/*X in a *X/*X combination was found, i.e. twelve
*13:03-*03:01/*X vs four *X/*X offspring (OR=3.0, P=4.6610
22).
This finding is consistent with an independent predisposing
effect of this haplotype and with a dominant model of in-
heritance. Data are shown in Table 2.
*04:05-*03:01. Similarly, inheritance of the *04:05-*03:01
haplotype was assessed in 52 families. There was no parent
carrying two copies of *04:05-*03:01. Between the mating type
*04:05-*03:01/*X by *X/*X (*X denotes haplotypes other than
*04:05-*03:01, *13:03-*03:01, *15:01-*06:02 and *03:01-*02:01),
there were 37 *04:05-*03:01/*X vs 13 *X/*X (OR=2.8,
P=6.9610
24). Between the mating type *04:05-*03:01/*X by
*04:05-*03:01/*X there were 2 *04:05-*03:01/*X vs 0 *X/*X
offspring. In total there were 39 *04:05-*03:01/*X vs 13 *X/*X
(OR=3.0, P=3.1610
24), supporting an independent predispos-
ing effect of this haplotype, which is coherent with a dominant
model of inheritance. Data are shown in Table 3.
*03:01-*02:01. Inheritance of the *03:01-*02:01 haplotype was
assessed after omitting all parents carrying one of the other
positively associated haplotypes (i.e., *03:01-*02:01, *13:03-
*03:01, *15:01-*06:02 and *04:05-*03:01). The analysis was
carried out in 435 families. There were 153 *03:01-*02:01/*X vs
104 *X/*X (OR=1.5, P=2.2610
23) offspring from the mating
type *03:01-*02:01/*X by *X/*X genotype, 41 *03:01-*02:01/*X
vs 13 *X/*X (OR=3.2, P=1.4610
24) offspring from the mating
type *03:01-*02:01/*X by *03:01-*02:01/*X parents. In total
there were 194 *03:01-*02:01/*X vs 117 *X/*X (OR=1.7,
P=1.3610
25) offspring. From the mating type *03:01-* 02:01/*X
by *03:01-*02:01/*X there were 58 *03:01-*02:01/*03:01-*02:01
vs 41 *03:01-*02:01/*X (OR=1.4, P=8.8610
22) and 49 *03:01-
*02:01/*03:01-*02:01 vs 17 *03:01-*02:01/*X (OR=2.9,
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25) offspring from the mating type *03:01-*02:01/
*03:01-*02:01 by *03:01-*02:01/*X parents. In total, there
were 107 *03:01-*02:01*/03:01-*02:01 vs 58 *03:01-*02:01/*X
(OR=1.8, P=1.4610
24) offspring. These results are consistent
with an independent effect of the haplotype, with a dominant
inheritance, and with an additive effect on risk, since
*03:01*0201/*X individuals had a risk 1.7-fold higher over the
*X/*X carriers, while a 1.8-fold risk was carried by the *03:01-
*02:01/*03:01-*02:01 individuals over the *03:01-*02:01/*X
subjects. Data are shown in Table 4.
Independence of the effect and mode of inheritance of
negatively associated haplotypes
*16:01-*05:02. The independence of the effect of the negatively
associated *16:01-*05:02 haplotype was assessed by examining its
inheritance either with the inclusion of parents carrying one or
more predisposing haplotypes, or without any of the predisposing
haplotypes. We denoted the predisposing haplotype with a *X, but
not the protective *15:02-*06:01 haplotype, and identified 428
available families. In total there were 165 *16:01- *05:02/*X versus
250 *X/*X (OR=0.7, P=3.0610
25). Offspring carrying two
copies of the *16:01-*05:02 haplotypes had 0.1-fold less risk
of developing MS compared to heterozygous individuals
(P=1.1610
27), which is consistent with an additive model. Data
are shown in Table 5.
To avoid effects due to the over-transmission of positively
associated haplotypes, the analysis was repeated for parents who
were negative for all of the associated haplotypes, and the
protective *15:02-*06:01 haplotype. Of the 108 families available
for our analysis, there was 1 *16:01- *05:02/*16:01-*05:02 vs 17
*16:01- *05:02/*X (OR=0.1, P=1.6610
24) and 52 *16:01-
*05:02/*X vs 50 *X/*X (OR=1.0, *X denotes haplotypes other
than *13:03-*03:01, *15:01-*06:02,*04:05-*03:01,* 03:01-*02:01
and *15:02-*06:01). The independence of the haplotype effect was
thus confirmed in homozygous individuals, since the presence of
Table 2. Inheritance of HLA-DRB1*13:03-DQB1*03:01 in the
absence of the other predisposing haplotypes DRB1*03:01-
DQB1*02:01, DRB1*15:01-DQB1*16:02, DRB1*04:05-
DQB1*03:01.
Mating genotype Offspring genotype
13/13 versus 13/X 13/X versus X/X
13/X by X/X NA 12 vs 4 (OR 3.0; P=4.6610
22)
13/X by 13/X 0 0
13/13 by 13/X 0 NA
Total (16 Families) 12 vs 4 (OR 3.0; P=4.6610
22)
Legend: HLA-DRB1*13:03DQB1*03:01 (13); all other haplotypes (X); p value (P).
NA means that offspring genotypes are not possible with parental genotypes.
doi:10.1371/journal.pone.0033972.t002
Table 1. Transmission disequilibrium test in 943 trios multiple sclerosis families.
Affected offspring Unaffected offspring
Haplotype DRB1-DQB1 T NT OR 95% C.I. P Pc x
2 T NT OR 95% C.I. P Pc x
2
DRB1*13:03-DQB1*03:01 40 14 2.9 1.6 5.4 3.6610
24 7.6610
23 12.7 71 1 0.6 0.2 1.6 3.4610
21 7.2610
0 0.7
DRB1*04:05-DQB1*03:01 115 50 2.4 1.7 3.4 2.1610
27 4.4610
26 32 37 0.9 0.5 1.4 5.4610
21 1.1610
1 1.4
DRB1*08:01-DQB1*04:02 21 9 2.4 1.1 5.1 2.8610
22 5.8610
21 4.8 470.6 0.2 2.0 3.6610
21 7.6610
0 2.9
DRB1*03:01-DQB1*02:01 464 264 2.1 1.7 2.4 4.9610
217 1.0610
215 127 159 0.7 0.6 1.0 3.2610
22 6.7610
21 3.2
DRB1*15:01-DQB1*06:02 40 21 1.9 1.1 3.3 1.4610
22 3.0610
21 6.0 14 8 1.8 0.7 4.2 2.0610
21 4.1610
0 0.1
DRB1*04:02-DQB1*03:02 32 18 1.8 1.0 3.2 4.6610
22 9.7610
21 4.0 12 12 1.0 0.4 2.2 1.0610
0 2.1610
1 0.1
DRB1*13:01-DQB1*06:03 24 20 1.2 0.7 2.2 5.4610
21 1.1610
1 0.4 51 1 0.5 0.2 1.3 1.3610
21 2.8610
0 3.6
DRB1*11:04-DQB1*03:01 118 105 1.1 0.9 1.5 3.7610
21 7.7610
0 0.8 44 42 1.1 0.7 1.6 8.2610
21 1.7610
1 0.4
DRB1*04:05-DQB1*03:02 76 69 1.1 0.8 1.5 5.5610
21 1.2610
0 0.4 36 30 1.2 0.7 2.0 4.5610
21 9.4610
0 0.0
DRB1*04:03-DQB1*03:02 36 34 1.1 0.7 1.7 8.1610
21 1.7610
1 0.1 15 14 1.1 0.5 2.2 8.5610
21 1.8610
1 0.5
DRB1*07:01-DQB1*02:01 73 83 0.9 0.6 1.2 4.1610
21 8.7610
0 0.7 26 27 1.0 0.6 1.7 8.9610
21 1.9610
1 0.6
DRB1*12:01-DQB1*03:01 25 31 0.8 0.5 1.4 4.2610
21 8.8610
0 0.7 13 11 1.2 0.5 2.7 6.8610
21 1.4610
1 2.0
DRB1*04:03-DQB1*03:04 27 34 0.8 0.5 1.3 3.7610
21 7.7610
0 0.8 15 11 1.4 0.6 3.0 4.3610
21 9.0610
0 0.9
DRB1*01:01-DQB1*05:01 68 89 0.8 0.5 1.0 8.6610
22 1.8610
0 2.9 28 33 0.8 0.5 1.4 5.1610
21 1.1610
1 0.0
DRB1*11:01-DQB1*03:01 97 133 0.7 0.5 0.9 1.4610
22 2.9610
21 6.1 53 42 1.3 0.8 2.0 2.4610
21 5.1610
0 0.1
DRB1*14:01-4-DQB1*05:031 29 44 0.7 0.4 1.0 7.6610
22 1.6610
0 3.2 19 10 1.9 0.9 4.2 9.1610
22 1.9610
0 0.0
DRB1*01:02-DQB1*05:01 44 73 0.6 0.4 0.9 6.3610
23 1.3610
21 7.5 19 19 1.0 0.5 1.9 1.0610
0 2.1610
1 0.1
DRB1*10:01-DQB1*05:01 27 47 0.6 0.4 0.9 1.9610
22 3.9610
21 5.5 10 8 1.3 0.5 3.2 6.3610
21 1.3610
1 0.0
DRB1*04:05-DQB1*02:01 16 31 0.5 0.3 0.9 2.8610
22 5.8610
21 4.9 10 5 2.0 0.7 5.9 1.9610
21 4.1610
0 0.5
DRB1*16:01-DQB1*05:02 177 321 0.5 0.4 0.6 2.6610
212 5.4610
211 94 85 1.1 0.8 1.5 4.7610
21 9.8610
0 2.2
DRB1*15:02-DQB1*06:01 10 37 0.3 0.1 0.5 7.3610
25 1.5610
23 15.7 11 8 1.4 0.6 3.5 4.9610
21 1.0610
1 0.1
Others (,1%) 101 133 44 48
Total 1600 1660 638 638
Legend: Transmission disequilibrium test (TDT); Transmitted (T); Not transmitted (NT); p value (P); p value corrected (Pc).
doi:10.1371/journal.pone.0033972.t001
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MS risk with respect to a single copy. Moreover, heterozygous
individuals had risk similar to neutral haplotype homozygous
carriers, which suggests a recessive inheritance mechanism of the
*16:01-*05:02 haplotype. Data are shown in Table 6.
With the limitation of a small number of families, we repeated
the analysis relative to the *15:02-*06:01 haplotype, as previously
done for the *16:01-*05:02 haplotype. After omitting families
carrying the protective *16:01-*05:02 haplotype, and including as
*X also those families with the predisposing *13:03-*03:01, *15:01-
*06:02, *04:05-*03:01 and *03:01-*02:01 haplotypes, only 28
families remained available for the analysis. There were six *15:02-
*06:01/*X vs 22 *X/*X offspring (OR=0.3, P=2.5610
23) from
the mating type *15:02-*06:01/*X by *X/*X parents, consistent
with a dominant model. Removal of the positively associated
haplotypes left no parents available for analysis, thus it was not
possible to confirm the independence effect. Data are reported
in Table 7.
Case and pseudocontrol analysis
A conditional logistic regression analysis was designed to
identify genotypes associated with MS and to evaluate potential
confounding interaction effects between haplotypes. Significant
associations were identified through a backward stepwise ap-
proach, consecutively eliminating from the model the interactions
that are not significant (P.5610
23). The analysis revealed six
significantly associated haplotypes. Potential data over-fitting
problems, leading to alpha error rate increases, were excluded
by performing 1000 random permutations within each matched
set. The same model was obtained using forward selection from
the null model. ORs of associated haplotypes relative to all non-
associated ones, denoted as DRB1*X-DQB1*X, showed that four
haplotypes increased the risk of MS: *04:05-*03:01 (OR=2.6,
95% CI 1.8–3.6,P=8.2610
28); *13:03-*03:01 (OR=3.2, 95% CI
1.7–6.0, P=2.0610
24); *15:01-*06:02 (OR=2.2, 95% CI 1.3–
3.8, P=4.0610
23); and *03:01- *02:01 (OR=1.8, 95% CI 1.5–
2.1, P=8.7610
212). Two haplotypes decreased risk: *16:01-
*05:02 (OR=0.7, 95% CI 0.6–0.9, P=4.1610
24) and *15:02-
*06:01 (OR=0.3, 95% CI 0.2–0.7, P=4.0610
23). The analysis
showed no significant interaction between haplotypes. A subse-
quent conditional logistic regression analysis was performed with a
backward stepwise approach to estimate the risk associated with
homozygous genotypes, and heterozygous genotypes consisting of
one predisposing or protecting haplotype combined with one
unassociated haplotype. The combined risk of two different
predisposing or protecting haplotypes was also estimated. The
carriage of two predisposing or protective haplotypes increased or
decreased MS risk according to a multiplicative model. The
genotype ranking, in decreasing order of risk was: from *04:05-
*03:01/*03:01-*02:01 (OR=4.5, 95% CI 2.2–9.3, P=4.3610
25);
*03:01-*02:01/*03:01-*02:01 (OR=4.1, 95% CI 2.9–5.8,
P=2.5610
215); and *16:01-*05:02/*16:01-*05:02 (OR=0.2,
95% CI 0.1–0.5, P=1.1610
23). Heterozygous individuals exhib-
ited the highest risk if they carried the *13:03-*03:01/*X
(OR=3.2, 95% CI 1.7–5.9, P=2.6610
24) genotype; followed
by *04:05-*03:01/*X (OR=2.8, 95% CI 1.9–4.0, P=2.2610
28);
*15:01-*06:02/*X (OR=2.2, 95% CI 1.3–3.8,P=4.8610
23);
*03:01-*02:01/*X (OR=1.40, 95% CI 1.2–1.7, P=3.9610
24);
and *16:01-*06:01/*X (OR=0.4, 95% CI 0.2–0.7, P=4.8610
23)
genotypes. The risk remained high for individuals with genotypes
combining one predisposing and one protective haplotype,
although P values were not significant and 95% CIs were large,
due to the scarce presence of such combinations. Data are
presented in Table 8.
Results were confirmed by relative predispositional effect (RPE)
analysis (data not shown).
Table 3. Inheritance of HLA-DRB1*04:05-DQB1*03:01 in the absence of the other predisposing haplotypes DRB1*03:01-
DQB1*=02:01, DRB1*13:03-DQB1*03:01, DRB1*15:01-DQB1*06:01.
Mating genotype Offspring genotype
4/4 versus 4/X 4/X versus X/X
4/X by X/X NA 37 vs 13 (OR=2.8; P=6.9610
24)
4/X by 4/X 0 vs 2 (OR=0; P=1.6610
21)2 vs 0( P=1 . 6 610
21)
4/4 by 4/X 0 vs 0N A
Total (52 Families) 0 vs 23 9 vs 13 (OR=3.0; P=3.0610
24)
Legend: HLA-DRB1*04:05-DQB1*03:01 (4); all other haplotypes (X); p value (P). NA means that offspring genotypes are not possible with parental genotypes.
doi:10.1371/journal.pone.0033972.t003
Table 4. Inheritance of HLA-DRB1*03:01-DQB1*02:01 in the absence of the other predisposing haplotypes DRB1*13:03-
DQB1*03:01, DRB1*15:01-DQB1*06:02, DRB1*04:05-DQB1*03:01.
Mating genotype Offspring genotype
3/3 versus 3/X 3/X versus X/X
3/X by X/X NA 153 vs 104 (OR=1.5; P=2.2610
23)
3/X by 3/X 58 vs 41 (OR=1.4; P=8.8610
22)4 1 vs 13 (OR=3.2; P=1.4610
24)
3/3 by 3/X 49 vs 17 (OR=2.9; P=8.5610
25)N A
Total (435 Families) 107 vs 58 (OR=1.8; P=1.4610
24) 194 vs 117 (OR=1.7; P=1.3610
25)
Legend: HLA-DRB1*03:01-DQB1*02:01 (3); all other haplotypes (X); p value (P). NA means that offspring genotypes are not possible with parental genotypes.
doi:10.1371/journal.pone.0033972.t004
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Since the two protective *16:01 and *15:02 alleles are serol-
ogically ‘‘split’’ from the DR2 as well as the predisposing *15:01
allele, we focused functional analysis on these three alleles
and evaluated sequences similarity by multiple alignment of
DRB1*15:01, *16:01 and *15:02. The variable residue at position
86, belonging to Pocket-1 of the DRB1 chain, is the only difference
between the protective (Gly86 in the *16:01 and in the *15:02
alleles) and predisposing (Val86 in the *15:01 allele) DR2 splits.
Similarly, we examined sequence similarity of DQB1 chain for the
predisposing *06:02 allele and the protective *05:02 and *06:01
alleles. Also in this case, the DQ partners of different DR2
presented a variation that is clearly linked to a/the predisposing/
protective allele typology. More precisely, this variable residue is
located at position 38, under Pocket-9, with Ala38 in the
predisposing DQB1*06:02 allele, and Val38 in the two protective
DQB1 *05:02 and *06:01 alleles. Sequence alignments are
reported in Table 9 and 10.
Discussion
The strong association between HLA-DRB1-DQB1 loci and
MS has been established across many populations, with consistent
findings indicating that predisposition is carried by the *15:01-*
06:02 haplotype in all populations of North-European ancestry
[4], while in Israel [11] and in Mediterranean [8–10] populations,
predisposition to the disease is carried by different DRB1*
variants. In the light of these findings it is interesting to note that
a recent genome-wide association study confirmed the *15:01
allele as the strongest genetic determinant in MS and, after
conditioning to the *15:01, an association with the DRB1*03:01
and the DQB1*02:01 alleles emerged. After further conditioning,
a third secondary association with the *13:03 allele was evident
[4].
Several studies indicated that the presence of alleles confers
resistance to the disease and modulates the permissive effect of the
*15:01 allele, thus suggesting that the autoimmune response may
be lowered or cancelled by the co-presence of both susceptible
and protective alleles. Indeed, two copies of the *15:01 allele
determined the highest risk [13], while the *15/*14 genotype
considerably lowered the risk of the disease [13–16]. However,
the extended DRB1*-DQB1*haplotype has not been taken into
account in these studies [13–16], despite findings that support the
effect of both DRB1*15:01 and DQB1*16:02 alleles [17,18] in MS
risk.
In Sardinia, an Italian island having a very high prevalence of
MS [21,22] and a peculiar genetic background [23], a heteroge-
neous HLA association with MS has been reported [24]. We re-
analysed the risk carried from HLA class II variants, and
specifically determined by both DRB1* and DQB1* alleles
(DRB1*- DQB1* haplotype) in a Sardinian MS family sample
more than twice as large as in our previous study [24]. Our
intent was to confirm the haplotype association, to establish the
independence of the associated haplotypes and assess the risk due
to the genotype.
First, the association was evaluated in 943 trio Sardinian
families. Using a highly conservative correction of P values, TDT
analysis confirmed that in Sardinia HLA-related MS susceptibility
is associated with *13:03-*03:01 (OR=2.9), *04:05-*03:01
(OR=2.4) and *03:01-*02:01 (OR=2.1) haplotypes, while
the previously reported over-transmission of a DRB1*15:01-
DQB1*06:02 haplotype was no longer found after correction for
multiple comparisons, so the previously reported over-transmission
of the DRB1*04:05-DQB1*03:02 haplotype was not confirmed. In
Table 5. Inheritance of HLA-DRB1*16:01-DQB1*05:02 in the absence of the negatively associated HLA-DRB1*15:02-DQB1*06:01.
Mating genotype Offspring genotype
16/16 versus 16/X 16/X versus X/X
16/X by X/X NA 132 vs 227 (OR=0.6; P=2.0610
22)
16/X by 16/X 4 vs 33 (OR=0.1; P=1,9610
26)3 3 vs 23 (OR=1.4; P=1.8610
21)
16/16 by 16/X 1 vs 8(OR=0.1;P=2.0 610
22)N A
Total (428 Families) 5 vs 41 (OR=0.1; P=1.1610
27) 165 vs 250 (OR=0.7; P=3.0610
25)
Legend: HLA-DRB1*16:01-DQB1*05:02 (16); X includes the positively associated DRB1*03:01-DQB1*02:01, DRB1*13:03-DQB1*03:01, DRB1*15:01-DQB1*06:02,
DRB1*04:05-DQB1*03:01 and ‘‘neutral’’ haplotypes; p value (P). NA means that offspring genotypes are not possible with parental genotypes.
doi:10.1371/journal.pone.0033972.t005
Table 6. Inheritance of HLA-DRB1*16:01-DQB1*05:02 (16) in the absence of the negatively associated HLA-DRB1*15:02-DQB1*06:0,
the positively associated DRB1*03:01-DQB1*02:01, DRB1*13:03-DQB1*03:01, DRB1*15:01-DQB1*06:02 and DRB1*04:05-
DQB1*03:01. X=‘‘neutral’’ haplotypes.
Mating genotype Offspring genotype
16/16 versus 16/X 16/X versus X/X
16/X by X/X NA 40 vs 41 (OR=1.0; P=9.1610
21)
16/X by 16/X 1 vs 12 (OR=0.1; P=2.3610
23)1 2 vs 9(OR=1.3;P=5.1 610
21)
16/16 by 16/X 0 vs 5 (OR=0; P=2.5610
22)N A
Total (108 Families) 1 vs 17 (OR=0.1; P=1.6610
24)5 2 vs 50 (OR=1.0; P=8.4610
21)
X=all other alleles ‘‘neutral’’ haplotypes.
Legend: HLA-DRB1*16:01-DQB1*05:02 (16); ‘‘neutral’’ haplotypes(X); p value (P). NA means that offspring genotypes are not possible with parental genotypes.
doi:10.1371/journal.pone.0033972.t006
HLA and Multiple Sclerosis in Sardinia
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e33972the second step, the independence of the effect of the various
associated haplotypes was assessed by inheritance analysis of each
associated haplotype, which may be transmitted from parents to
affected offspring, removing other associated haplotypes. Inde-
pendence of the positively associated *13:01-*03:01, *04:05-*03:01
and *03:01-*02:01 haplotypes was thus established. The presence
of one copy of the haplotype vs two copies of neutral haplotypes
was sufficient to increase the risk, thus showing that all
predisposing haplotypes are inherited according to a dominant
model. An additive effect on risk was observed relative to the
*03:01-*02:01 haplotype. In offspring carrying one copy of this
haplotype had a risk that was 1.7 times higher than for those
carrying neutral haplotypes (that are all non associated haplo-
types); while homozygous individuals had a 1.8-fold higher risk
than heterozygous ones.
TDT analysis showed that two haplotypes, namely *16:01-
*05:02 (OR=0.5) and *15:02-*06:01 (OR=0.3), were under-
transmitted. To remove the possibility of an over-transmission
bias, the haplotype inheritance from parents was studied by
removing all positively associated haplotypes. The protective effect
of *16:01-*05:02 was confirmed in homozygous vs heterozygous
patients (OR=0.1), as occurs in a recessive model; while
heterozygous individuals showed the same risk of their offspring
carrying two copies of the neutral haplotypes (OR=1.0).
The relative rarity of the *15:02-*06:01 haplotype precluded
the possibility of determining, by analysis alone, a real effect
for haplotype under- transmission in the absence of susceptible
haplotypes. Thus, the independence of the effect has not been
established. However, findings obtained using the RPE method,
indicate that the negative association of *15:02-*06:01 haplotype
with MS was not due to a displacement effect driven by the
positively associated haplotypes. It is important to observe that, the
negative associations were not detected in previous RPE analyses
[24]. This apparent contradiction is likely due to both the high
frequency of the *16:01-*05:02 haplotype and the low frequency of
the *15:02-*16:01 haplotype in the general Sardinian population
(18.8% and 1.6%, respectively, in 2756 chromosomes from
healthy individuals, data not shown), which would require an
adequately large sample size [25] for an affordable analysis.
Positive and negative associations were further confirmed by
examining the risk as determined by genotype. Logistic regres-
sion analysis of associated haplotypes in comparison to all non-
associated ones, showed that four haplotypes significantly in-
creased the risk of MS: *04:05-*03:01 (OR=2.6); *13:03-*03:01
(OR=3.2); *15:01-*06:02 (OR=2.2); and *03:01- *02:01
(OR=1.8); while two haplotypes decreased the risk, *16:01-
*05:02 (OR=0.7) and *15:02-*06:01 (OR=0.3). Contrary to
some analyses in other populations, where a recessive effect of the
*03:01 allele has been reported [17,21,26], but in agreement with
data from Canadian population [14]; our analysis consistently
confirmed the dominant effect of this allele. Within the logistic risk
framework a dose effect was also observed in ‘‘at risk’’ homozygous
individuals, as in compound heterozygous individuals, according
to an additive model. Thus, the highest risk was conferred by
*04:05-*0301/*03:01-*02:01 (OR=4.5); followed by *03:01-
*02:01/*03:01-*02:01 (OR=4.1). In contrast, while *16:01-
*05:02/*16:01-*05:02 decreased the risk (OR=0.2), one copy
alone of *16:01-*05:02 was not sufficient to confer protection in
genotypes that combine this haplotype with a predisposing one.
Consistent with the findings from haplotype inheritance analyses,
the effect of MS associated DRB1-DQB1 genotypes delineates a
model constituted by a dominantly acting susceptibility gene
contained on, or near to, the *04:05-*03:01, *13:03-*03:01,
*03:01-*02:01 haplotypes, in conjunction with the absence of a
protective gene required for the maintenance of peripheral
tolerance. Another example of allelic interactions acting in human
disease comes from type 1 diabetes, where the greater relative risk
is carried by the DRB1*03 and *04 when compared with
DRB1*03 or *04 homozygous [27]. The same effect appears in
celiac disease, where the risk is increased in carriers of the
DQA1*05-DQB1*02 alleles either in trans or in cis [28].
Table 7. The inheritance of HLA-DRB1*15:02-DQB1*06:01 (*15:02) in the absence of HLA-DRB1*16:01-DQB1*05:02.
Mating genotype Offspring genotype
*15:02/*15:02 versus *15:02/X *15:02/X versus X/X
*15:02/X by X/X NA 6 vs 22 (OR=0.3; P=2.5610
23)
*15:02/X by *15:02/X 0 0
*15:02/*15:02 by *15:02/X 0 NA
Total (28 Families) 6 vs 22 (OR=0.3; P=2.5610
23)
Legend: HLA-DRB1*15:02-DQB1*06:01 (*15:02); X includes the positively associated DRB1*03:01-DQB1*02:01, DRB1*13:03-DQB1*03:01, DRB1*15:01-DQB1*06:02,
DRB1*04:05-DQB1*03:01 and ‘‘neutral’’ haplotypes; p value (P). NA means that offspring genotypes are not possible with parental genotypes.
doi:10.1371/journal.pone.0033972.t007
Table 8. HLA DRB1*-DQB1* genotypes from 943 multiple
sclerosis patients and 362 healthy siblings, plus 2829
pseudocontrols obtained from healthy parents of the 943 trio
families.
HLA DRB1*-DQB1* genotype P OR 95% CI
03:01-02:01/03:01-02:01 2.5610
215 4.1 2.9 5.8
16:01-05:02/16:01-05:02 1.1610
23 0.2 0.1 0.5
04:05-03:01/X 2.2610
28 2.8 1.9 4.0
13:03-03:01/X 2.6610
24 3.2 1.7 5.9
15:01-06:02/X 4.8610
23 2.2 1.3 3.8
03:01-02:01/X 3.9610
24 1.4 1.2 1.7
16:01-05:02/X 1.1610
22 0.8 0.6- 0.9
15:02-06:01/X 4.8610
23 0.4 0.2 0.7
04:05-03:01/03:01-02:01 4.3610
25 4.5 2.2 9.3
04:05-03:01/16:01-05:02 8.6610
23 4.5 2.2 9.3
13:03-03:01/03:01-02:01 1.5610
22 6.7 1.4 31.2
13:03-03:01/16:01-05:02 4.4610
22 9.4 1.1 84.0
15:01-06:02/03:01-02:01 3.9610
22 3.7 0.5 7.7
Legend: X=all not associated haplotypes. P values threshold is set at 0.005.
doi:10.1371/journal.pone.0033972.t008
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*15:01 allele is virtually absent; while the *16:01 is common [23],
inverting the proportion of the allele frequencies as observed in
North-European populations [4]. For the two alleles *16:01 and
*15:02, we found a negative association with MS in the Sardinian
families, and observed that both are ‘‘splits’’ of the serological
group DR2, as is the susceptibility *15:01 allele [29]. A direct
comparison of DRB1 sequence of *15:01, *16:01 and *15:02 was
thus affected by multiple alignment. The variable residue at
position 86 of the DRB1 protein chain is the only one that
differentiated between the protective and the predisposing DR2
alleles [30]. Position 86 is one of the residues defining Pocket-1,
which is fundamental for the correct positioning of the antigen
peptide in the binding site [31]. As already described [31], when a
Valine is present (as in the *15:01) the interaction with small
aliphatic residues is favoured, while when a Glycine is present (as
for *1502 and *1601), binding of large aromatic residues of the
peptide is favoured. Similarly, we compared the DQB1 chains for
the predisposing *06:02 allele and the protective *05:02 and
*06:01 alleles. The DQ partners of different DR2 alleles presented
a striking residue variation, this time at position 38, which
mirrored the same kind of classification observed for DRB1. In
particular, Ala38 is present in the predisposing *06:02, while
Val38 is observed in both the protective alleles, *05:02 and *06:01.
Position 38 is located under Pocket-9, composed by residues 30, 37
and 57. The Alanine to Valine change may determine some
modifications to the respective positions of the residue in Pocket-9,
thus impacting upon the binding mode. In particular, the main
effect is likely due to steric properties, because the Valine side
chains occupy a larger volume than Alanine side chains. Note that
the DQB1 Pocket-9 residue Asp57 has a protective effect against
some kinds of type 1 diabetes [32,33]. A molecular explanation
might be that, in the presence of Asp57, a saline bridge is formed
between Asp57 and a conserved Arg79, locking Arg79 so that it is
no longer free to interact with negatively charged P9 peptide
residues (as in the case of non-Asp57 residue).
A role for the Val86 residue in MS susceptibility has been
reported in Swedish [33] and Australian [34] populations. The
differences in residues of the DRB1 and their cognate DQB1
chains observed in Sardinian MS patients could account for the
different strength of association that characterises the disease-
predisposing *15:01 allele and the pair of disease-protective *16:01
and *15:02 alleles. This implies a high degree of specificity for
encephalitogenic molecules, as demonstrated for the DRB1 chain
Val86 residue [30]. The high LD across the *15:01-*06:02
haplotype make it problematic to dissect whether the primary
association is with the DRB1* or with the DQB1 molecules.
Findings from African-American MS patients seem to support the
idea that DRB1* is the primary driver of the association [35], but
other data indicate that both DRB1 and DQB1 molecules are
fundamental players in determining individuals’ MS risk [19]. The
present data from a Sardinian population suggest that both DRB1
and DQB1 chains contribute to MS predisposition, highlighting
the importance of the amino acid residue in binding pockets and
surrounding areas, particularly concerning their steric and the
electrostatic properties. However, these findings do not explain
why several phylogenetically different [36,37] DRB1-DQB1
haplotypes harbour genetic susceptibility to MS in Sardinian
and in other populations. One can hypothesise that each of these
permissive haplotypes presents different myelin basic protein
epitopes, or different autoantigens, in a sophisticated specialized
way, but detailed functional studies from transgenic animal MS
models would be required for proof.
In conclusion, the findings presented here demonstrate that
independent, but associated, DRB1*-DQB1* haplotypes confer
susceptibility and resistance to MS in the MS-prone Sardinian
population. We suggest that similarities and differences in specific
residues of the DRB1 and DQB1 chains may contribute to genetic
predisposition for MS. In this regard, studies from genetically
selected and homogeneous populations may contribute to a better
understanding of the role of both DRB1* and DQB1* alleles in the
MS autoimmune process.
Table 9. Multiple Sequence alignments of the predisposing and protective alleles considered in the study, with only variable
amino acid residues reported, for the three DRB1 alleles (*15:02, *16:01, *15:01) belonging to serological group DR2.
Position CLASS 9 1 01 11 21 34 75 76 77 07 17 47 78 6
DRB1*15:02 Protective W QPKRFDI QAATG
DRB1*16:01 Protective WQPKRYDFDRATG
DRB1*15:01 Predisposing W QPKRFDI QAATV
Pockets P9 P6 P4 P7 P9 P7 P4 P4 P1
P6 P7
The pockets to which resides belong to are indicated in the last two lines.
doi:10.1371/journal.pone.0033972.t009
Table 10. Multiple Sequence alignments of the predisposing and protective alleles considered in the study, with only variable
amino acid residues reported, for the three DQB1 alleles (*06:01,*05:02,*06:02).
Position CLASS 9 1 31 42 62 83 03 73 85 55 77 47 57 78 48 58 6
DQB1*06:01 Protective LAM YTYDV RDELTEVA
DQB1*05:02 Protective YGLGTHYV RSSVREVA
DQB1*06:02 Predisposing FGM LTYYA RDELTEVA
Pockets P6 P4 P4 P4 P6 P9 P9 P4 P1
doi:10.1371/journal.pone.0033972.t010
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Patients
We examined 943 MS families consisting of one affected sibling
and both healthy parents (trio), and 362 healthy siblings (one from
each family) of patients coming from the same families. Of these,
448 families have already been reported [24] while 495 constituted
an independent sample. All patients participating in the study
attended the MS Clinic at University of Cagliari (Italy). The study
was conducted in accordance with the Helsinki Declaration and
approved by University of Cagliari/ASL8 (Italy) ethics committee.
All subjects gave informed written consent.
All patients included in the study met MS criteria [38,39]. The
study cohort included healthy subjects and Sardinian MS patients,
many of them had a Sardinian ancestry of three generations or
more. The sample included in the study was representative of the
total Sardinian MS population consisting in about half of the
estimated Sardinian population with MS (the actual Sardinian
population is about 1 million and 550,000 inhabitants). Subjects
included in the study came from each Sardinian province, and
were present in proportion to the number of inhabitants of each
province.
Genotyping
Typing of the HLA-DRB1* and -DQB1* loci was performed as
described elsewhere [24]. Briefly, the polymorphic second exon
of the HLA-DRB1* and -DQB1* genes was amplified and the
amplified products were dot-blot analysed using primers and SSO
probes as described previously [24]. A total of 3191 individuals
were thus typed.
Statistical analysis
Transmission disequilibrium test analysis. Transmission
of haplotypes was assessed by the TDTphase program (version
2.403) for the 943 trio families. The TDT counts the number of
time a haplotype is transmitted from heterozygous parents to
offspring. The x
2 distribution was used to assess significance. Only
haplotypes present in at least 1% of sample were considered,
grouping together the others. A highly conservative Bonferroni
correction to P values (Pc) for the total number of haplotypes
investigated (N=21) was applied.
The Relative predispositional effect method. The RPE
method [40] was used to confirm the results obtained using
conditional logistic regression analysis. It sequentially compares
allele frequencies in patients and pseudocontrols to determine their
predisposition, protective, or neutral effects relative to each other.
Inheritance analysis of predisposing/protective DRB1-
DQB1 haplotypes. To examine the independence of each
associated haplotype’s effect, segregation of the haplotypes was
assessed in various mating types from the DRB1*-DQB1* parental
genotype [16]. Transmission of each positively associated
haplotype was examined in the offspring of parents carrying the
specific haplotype (1 copy or two copies); and of parents carrying 1
copy or 0 copies of the haplotype, after removing all the other
associated haplotypes. The unassociated haplotypes were included
in the analysis and denoted as *X. Alternatively, inheritance of
each negatively associated haplotype was assessed from parents
carrying, or missing, all the positively associated haplotypes. ORs
were obtained by comparing the number of offspring inheriting
two copies of the haplotype on analysis (A/A) versus those carrying
one copy (A/*X), and comparing the number of offspring who
inherited one copy (A/*X) versus those carrying 0 copies (*X/*X)
obtained from the various parental mating types.
Case and pseudocontrol analysis. Genetic data of the 943
trio families, consisting of parents with a single affected offspring,
were available for use. The control population consists of 362
healthy siblings and 2829 pseudocontrols obtained from the trio
families; from each trio three pseudo-controls were derived from
the three other possible combinations of haplotypes that could be
transmitted from the parents. Each case was matched to three
pseudo-controls [41]. A conditional logistic regression analysis was
designed to identify haplotypes associated to MS and to evaluate
potential confounding and interaction effects. At first, the
haplotypes having a occurrence of at least 10 were considered as
independent variables and inserted in the logistic model as
‘‘indicator variables’’; haplotypes with an occurrence lower than
10 were grouped and inserted in the model as a reference group.
Significant associations were identified through a backward
stepwise approach, consecutively eliminating from the model the
interactions and the haplotypes considered not significant
(P.5610
23).
Possible data over-fitting effects, which would have increased
alpha error rates, were managed by performing 1000 random
permutation within each matched set. A subsequent conditional
logistic regression analysis was performed with a backward
stepwise approach to produce estimates of the MS risk associated
with homozygous genotypes, and heterozygous genotypes consist-
ing of one predisposing or protecting haplotype combined with
one non associated haplotype referred to as ‘‘X’’. The combined
risk of two different predisposing or protecting haplotypes was also
estimated. In order to adjust for multiple testing the alpha level
was set at 0.005.
Sequences alignment and structural analysis. Complete
sequences of predisposing and protective haplotypes where
obtained from the IMGT/HLA database (http://www.ebi.ac.
uk/imgt/hla/) [42]. Sequences were aligned with the online tool
Clustalw (http://www.ebi.ac.uk/Tools/clustalw2) [43] and bind-
ing pockets were then identified based on the annotation from
Stern et al. [44] for DRB1* alleles. Based on the crystal structures
of DQB1*06:02 from Siebold et al. [45], and of DQB1 03:02 from
Lee et al. [46], the DQB1* pockets were defined as the set of
residues within a 6 A ˚ radius sphere centred on the peptide beta
carbon atoms.
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